{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
U.S. Physical Therapy, Inc.
Is U.S. Physical Therapy, Inc. technically bullish or bearish?
As of October 31, 2025, U.S. Physical Therapy, Inc. shows a mildly bullish trend overall, with mixed technical indicators and underperformance compared to the S&P 500, having a year-to-date return of -2.01% versus the S&P's 16.30%.
U.S. Physical Therapy, Inc. Experiences Revision in Its Stock Evaluation Amid Market Dynamics
U.S. Physical Therapy, Inc. has recently adjusted its valuation, with its stock price at $86.27. Over the past year, the company has seen a 7.60% return, lagging behind the S&P 500. Key metrics include a P/E ratio of 28 and a dividend yield of 198.40%, reflecting its financial standing in the sector.
Is U.S. Physical Therapy, Inc. technically bullish or bearish?
As of October 31, 2025, U.S. Physical Therapy, Inc. shows a mildly bullish technical trend, supported by bullish daily moving averages and a weekly MACD, despite underperforming the S&P 500 with a year-to-date return of -2.75%.
Is U.S. Physical Therapy, Inc. technically bullish or bearish?
As of October 31, 2025, U.S. Physical Therapy, Inc. shows a mildly bullish trend overall, with mixed signals from indicators and underperformance compared to the S&P 500.
U.S. Physical Therapy, Inc. Experiences Revision in Its Stock Evaluation Metrics
U.S. Physical Therapy, Inc. has recently adjusted its valuation, with a P/E ratio of 28 and a price-to-book value of 2.70. The company boasts a high dividend yield of 198.40% and solid profitability metrics, including a ROCE of 10.06% and ROE of 9.58%, reflecting strong operational efficiency.
Is U.S. Physical Therapy, Inc. overvalued or undervalued?
As of October 24, 2025, U.S. Physical Therapy, Inc. is considered overvalued with a P/E ratio of 28 and an EV to EBITDA of 17.32, showing lower stock performance at 13.73% compared to the S&P 500's 16.90%.
U.S. Physical Therapy, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics
U.S. Physical Therapy, Inc. has recently revised its evaluation amid changing market conditions. The stock is currently priced at $89.53, reflecting a year of notable performance fluctuations. Technical indicators present a mixed outlook, while the company has outperformed the S&P 500 in both weekly and annual returns.
U.S. Physical Therapy Experiences Revision in Its Stock Evaluation Amid Market Dynamics
U.S. Physical Therapy, Inc. has recently adjusted its valuation, with its stock price at $88.94. The company has experienced volatility over the past year, with a high of $101.19 and a low of $62.77. Key financial metrics indicate a competitive position within the Pharmaceuticals & Biotechnology sector.
Is U.S. Physical Therapy, Inc. technically bullish or bearish?
As of October 3, 2025, U.S. Physical Therapy, Inc. shows a bullish technical trend with positive indicators like the weekly MACD and Bollinger Bands, although caution is advised due to a bearish monthly KST and underperformance compared to the S&P 500 over the past year.
Is U.S. Physical Therapy, Inc. technically bullish or bearish?
As of October 3, 2025, U.S. Physical Therapy, Inc. shows a bullish technical trend with strong indicators, despite underperforming the S&P 500 in longer-term returns.
Is U.S. Physical Therapy, Inc. overvalued or undervalued?
As of October 3, 2025, U.S. Physical Therapy, Inc. is considered overvalued with a valuation grade of expensive, reflected by its high P/E ratio of 28 and lower stock performance of 10.12% compared to the S&P 500's 17.82%.
U.S. Physical Therapy, Inc. Experiences Revision in Its Stock Evaluation Amid Market Dynamics
U.S. Physical Therapy, Inc. has adjusted its valuation, reflecting shifts in financial metrics within the Pharmaceuticals & Biotechnology sector. The company exhibits a competitive P/E ratio of 28, a price-to-book value of 2.70, and a notable dividend yield of 198.40%, indicating its relative market position.
Is U.S. Physical Therapy, Inc. overvalued or undervalued?
As of September 26, 2025, U.S. Physical Therapy, Inc. is fairly valued with a P/E ratio of 28 and has underperformed the S&P 500 over one and five years, indicating it is not keeping pace with broader market gains.
U.S. Physical Therapy Stock Forms Golden Cross, Signals Bullish Breakout Ahead
U.S. Physical Therapy, Inc. has recently experienced a Golden Cross, indicating a potential shift in momentum. The stock has risen 3.5% today and 3.83% over the past week, contrasting with the S&P 500's performance. However, mixed technical indicators suggest ongoing long-term challenges despite short-term improvements.
Is U.S. Physical Therapy, Inc. technically bullish or bearish?
As of August 7, 2025, U.S. Physical Therapy, Inc. shows a mildly bearish trend with mixed signals across time frames, underperforming the S&P 500 with year-to-date and one-year returns of -9.65% and -5.18%, respectively.
Is U.S. Physical Therapy, Inc. overvalued or undervalued?
As of September 8, 2025, U.S. Physical Therapy, Inc. is fairly valued with a P/E ratio of 28, a Price to Book Value of 2.70, and an EV to EBITDA ratio of 17.32, despite underperforming the S&P 500 with a year-to-date return of -9.65%.
Is U.S. Physical Therapy, Inc. overvalued or undervalued?
As of May 8, 2025, U.S. Physical Therapy, Inc. is considered overvalued with a P/E ratio of 28 and an EV to EBITDA of 17.32, significantly higher than peers like Amedisys, Inc., and has underperformed the S&P 500 with a year-to-date return of -14.73%.
Is U.S. Physical Therapy, Inc. technically bullish or bearish?
As of May 9, 2025, the market trend is mildly bearish due to daily moving averages and monthly MACD signals, despite some mildly bullish indicators on the weekly timeframe, resulting in a weak bearish stance overall.
Who are in the management team of U.S. Physical Therapy, Inc.?
As of March 2022, the management team of U.S. Physical Therapy, Inc. includes Edward Kuntz (Independent Chairman), Christopher Reading (President and CEO), Reginald Swanson, Mark Brookner, Harry Chapman, Kathleen Gilmartin, and Bernard Harris (all Independent Directors). They oversee the company's operations and strategic direction.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
